Riverwater Partners’s Bristol-Myers Squibb BMY Stock Holding History

Riverwater Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,583	Closed	-$266K	–	197
2023 Q3	$266K	Buy	4,583 +689	+18%	+$42.2K	0.24%	152
2023 Q2	$249K	Sell	3,894 -320	-8%	-$21.5K	0.22%	152
2023 Q1	$292K	Sell	4,214 -78	-2%	-$5.5K	0.27%	119
2022 Q4	$309K	Sell	4,292 -2,003	-32%	-$151K	0.26%	125
2022 Q3	$448K	Buy	+6,295	New	+$457K	0.45%	70

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Riverwater Partners's BMY Position: Q4 2023 in Review

Riverwater Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 4,583 shares — an estimated $266K sold.

Riverwater Partners first reported a position in BMY in Q3 2022 and held it in 5 quarters. The position peaked at $448K in Q3 2022. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Riverwater Partners reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Riverwater Partners sold 4,583 Bristol-Myers Squibb shares in Q4 2023, an estimated $266K.
Riverwater Partners first reported a position in Bristol-Myers Squibb in Q3 2022 and held it in 5 quarters.
Riverwater Partners's Bristol-Myers Squibb position peaked at $448K in Q3 2022.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Riverwater Partners's 13F filing for Q4 2023, filed 5 Jan 2024.